Biosimulation Market worth $9.18 billion by 2029
The global biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. The major factors driving the growth of the biosimulation market include the high rate of clinical trial failures, the growing necessity of being able to predict drug pharmacokinetics and pharmacodynamics, as well as toxicity management. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The possible reasons stated for the failure include lack of clinical efficacy, unmanageable toxicity, poor drug-like properties, lack of commercial needs, and poor strategic planning. The use of biosimulation helps address these challenges to increase the chances of drug approval and facilitate swift trial processes.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=838
Browse in-depth TOC on "Biosimulation Market"
153 - Tables
54 - Figures
350 - Pages
By application, the drug discovery segment is
expected to capture the largest share of the biosimulation market. This large
share is attributed to the rising burden of chronic and infectious diseases,
coupled with technological advancements that enhance understanding of disease
mechanisms. Some other drivers for the drug discovery segment include the
emphasis on personalized medicine, increased investment in drug discovery, and
supportive regulatory frameworks.
Pharmaceutical and biotechnology companies are expected to
hold a major share of the biosimulation market by end users. Companies have
been putting in much effort in new drug discovery and development, having
strong candidate drugs in their pipelines. With stringent regulatory
requirements, pharma and biotech companies heavily rely on biosimulation tools
to support clinical trial designs and optimize therapeutic dosing. In 2023, the
US FDA approved 55 novel drug therapies, while as of 2024, 36 novel drug therapies
have been approved so far, reflecting the scope of the segment and its
substantial large market share.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=838
The major players in the biosimulation market with a
significant global presence are Certara USA. (US), Simulations Plus. (US),
Dassault Systèmes (France), Schrödinger, Inc. (US), Advanced Chemistry
Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa &
Co. LLC. (US), Genedata AG (US), Physiomics Plc (United Kingdom), In Silico
Biosciences. (US), Allucent. (US), OpenEye, Cadence Molecular Sciences. (US),
Cellworks Group, Inc. (US), VeriSIM Life. (US), Netabolics SRL (Italy), Charnwood
Discovery (United Kingdom), The MathWorks, Inc. (US), ANSYS, Inc (US), Instem
Group of Companies (United Kingdom), Insilico Medicine (US), SCM – Software
Chemistry & Materials (Netherlands), BioSymetrics, Inc. (Canada), Atomwise
Inc. (US), insitro. US), and Clinithink. (US). The market players have adopted
strategies such as acquisitions, collaborations, partnerships, mergers,
product/service launches & enhancements, and approvals to strengthen their
position in the biosimulation market. The product and technology innovations
have helped the market players expand globally by providing biosimulation and
modeling solutions.
Certara USA.:
As a global leader in manufacturing software and services
for drug discovery and development, Certara provides Model-informed Drug
Development (MIDD) software solutions to support all stages of drug
development, from preclinical through clinical and commercial. Its proprietary,
end-to-end platform integrates generative AI technology with biosimulation,
regulatory science, and market access solutions. The company boasts a strong
presence in North America, Europe, and Asia Pacific. The customer base includes
more than 2,400 biopharmaceutical companies, academic institutes, and
regulatory agencies from 66 countries.
Dassault Systèmes:
Dassault Systèmes is a multinational software company that
develops and sells 3D design software and intelligence products for modeling
and simulation. The company offers a number of products and services -
3DEXCITE, 3DEXPERIENCE, 3DVIA, BIOVIA, DraftSight, CATIA, DELMIA, ENOVIA,
EXALEAD, GEOVIA, NETVIBES, SIMULIA, for multiple industries, including
aerospace & defence, architecture, engineering & construction, consumer
goods & retail, consumer packaged goods & retail, energy, process &
utilities, financial and business services, high-tech, industrial equipment,
life sciences, marine & offshore, natural resources, and transportation
& mobility. Dassault Systèmes operates in 140 countries with more than 194
offices across North America, Europe, Asia-Pacific, Latin America, the Middle
East, and Africa, serving more than 270,000 customers.
Schrödinger:
Schrödinger is a scientific leader in developing
state-of-the-art chemical simulation software for pharmaceutical and
biotechnology research. It operates through two business segments: software and
drug discovery. The company provides products ranging from general molecular
modeling programs to a full-featured drug design software suite using
ligand—and structure-based methods. Schrödinger has a geographical presence in
the US, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, Inquire
Now!
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine offering to drive
supernormal growth for progressive organizations in the B2B space. We have the
widest lens on emerging technologies, making us proficient in co-creating
supernormal growth for clients.
Earlier this year, we made a formal transformation into one
of America's best management consulting firms as per a survey conducted by
Forbes.
The B2B economy is witnessing the emergence of $25 trillion
of new revenue streams that are substituting existing revenue streams in this
decade alone. We work with clients on growth programs, helping them monetize
this $25 trillion opportunity through our service lines - TAM Expansion,
Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account
Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive
ecosystem. Our insights and strategies are molded by our industry experts,
cutting-edge AI-powered Market Intelligence Cloud, and years of research. The
KnowledgeStore™ (our Market Intelligence Cloud) integrates our research,
facilitates an analysis of interconnections through a set of applications,
helping clients look at the entire ecosystem and understand the revenue shifts
happening in their industry.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
UK +44-800-368-9399
Email: sales@marketsandmarkets.com
Comments
Post a Comment